Trials / Completed
CompletedNCT00068042
A Study To Compare The Efficacy And Safety Of Pegvisomant To That Of Sandostatin Lar Depot In Patients With Acromegaly
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 100 (planned)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to determine if Pegvisomant is more efficacious than Sandostatin LAR Depot in normalizing IGF-I levels in treatment naive patients with acromegaly.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pegvisomant | |
| DRUG | Sandostatin LAR |
Timeline
- Start date
- 2003-04-01
- Completion
- 2006-05-01
- First posted
- 2003-09-08
- Last updated
- 2008-04-07
Locations
55 sites across 13 countries: United States, Australia, Brazil, Canada, France, Germany, Greece, Ireland, Italy, Norway, Spain, Sweden, United Kingdom
Source: ClinicalTrials.gov record NCT00068042. Inclusion in this directory is not an endorsement.